Related Experiment Video
Updated: Jul 21, 2026
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
[A new model of human prostate cancer, the PAC120 xenograft]
Abstract:
Prostate cancer is the second cause of cancer death in men. Often, initialy hormono-independent, escape from anti-androgen therapy is a key event of tumoral progression showing an hormone-independent phenotype. To study morphological, genetic and molecular bases associated with the hormono-dependence escape, a new model of human adenocarcinoma prostate xenograft, PAC120, was established with its hormono-dependent and independent variants. Its growth was strongly inhibited by surgical castration or by administration of the new gonadotrophin-releasing hormone antagonist, FE 200486 (Ferring, San Diego, CA). Evolution to hormono-independence was frequently associated with a mucoid differentiation or a neuroendocrine-like pattern, with the apparition of new chromosomic alterations and variations of human gene expressions. PAC120 xenograft is a new model of hormone-dependent prostate cancer, opening the opportunity to study the hormone dependence escape mechanism and to evaluate the efficacity of new therapeutics.
Insights
Researchers developed a new prostate cancer model (PAC120) to study how tumors become resistant to hormone therapy. This model helps investigate treatment resistance and explore new therapeutic strategies for advanced prostate cancer.
Area of Science:
- Oncology
- Cancer Biology
- Genetics
Background:
- Prostate cancer is a leading cause of cancer-related death in men.
- Hormone therapy resistance is a critical factor in prostate cancer progression.
- Understanding the mechanisms of hormone independence is crucial for developing effective treatments.
Discussion:
- The study introduces the PAC120 xenograft model, including hormone-dependent and independent variants.
- This model allows for the investigation of morphological, genetic, and molecular changes associated with treatment resistance.
- FE 200486, a novel gonadotrophin-releasing hormone antagonist, demonstrated significant inhibition of tumor growth.
Key Insights:
- Hormone independence in prostate cancer is often linked to mucoid or neuroendocrine differentiation.
- Acquisition of new chromosomal alterations and altered gene expression patterns are observed during the transition to hormone independence.
- The PAC120 model provides a valuable platform for studying the escape mechanisms from hormone dependence.
Outlook:
- The PAC120 xenograft model offers a novel tool for preclinical research in prostate cancer.
- It facilitates the evaluation of novel therapeutic agents targeting hormone-dependent and resistant prostate cancer.
- Further research using this model can lead to improved treatment strategies and better patient outcomes.
